Enabling Powerful POC and Mobile Diagnostics

LamdaGen Corporation is a privately held developer of nano-based biosensors and powerful testing systems.  The Company’s core diagnostic technology is a quantitative immuno-based platform that combines the high sensitivity of an ELISA with the simplicity and speed of LFA to enable quantitative detection of diseases, pathogens and contaminants.

There is a global need for advanced technologies that enable highly sensitive and quantitative detection to provide precise results at point of use in ~15 minutes.

To meet this need, LamdaGen has developed L’AuRa – a category-defining digital testing platform that enables significant performance and use advantages vs multi-hour ELISA’s and Lateral Flow assays.

LamdaGen’s L’AuRa digital technology enables robust diagnostic systems that are simple, compact and cost effective – with no moving parts and no wash steps. L’AuRa’s flexible designs range from miniaturized handhelds to small desktops to lab-based throughput systems – each providing powerful on the spot performance including  – rapid fifteen minute quantitative assays with LOQ’s into the low pg/mL or parts per trillion (PPT) range*

LamdaGen licenses its sensing technologies on an open-source basis to companies in the following sectors.

*Model dependent

LamdGen’s Micro-8 nano-based LSPR biosensors for multiplexed rapid and precise diagnostics

LamdGen’s Micro-8 nano-based biosensors for multiplexed targets


L’AuRa Digital Diagnostics

The L’AuRa diagnostic system is ideal for enabling high sensitivity, quantitative POC, mobile rapid testing.

Learn More ›

LSPR Biosensors

LamdaGen’s metallic thin-film LSPR-based Optical Biosensors for research and development in the areas of Life Science and Cleantech.

Learn More ›

News & Literature

LamdaGen and Arisan Receive $2 M NIH SBIR Phase II Grant to Advance Development of a Single, Rapid POC Assay for Detection of Acute Dengue and Zika Viral Infections Read More ...

Introducing L’AuRa – the result of diligent discovery, state of the art nano-science and a collaborative team penchant for uncompromising precision Read More ...

LamdaGen Corporation Receives Notice of Allowance to Grant European Patent for Enzymatic Assays Performed on LSPR Based Plasmonic Nano-Sensors Read More ...

More News >